<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ALEFACEPT <img border="0" src="../images/pr.gif"/></span><br/>(a-le'fa-cept)<br/><span class="topboxtradename">Amevive<br/></span><b>Classifications:</b> <span class="classification">biologic response modifier</span>; <span class="classification">fusion protein</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>15 mg vials</p>
<h1><a name="action">Actions</a></h1>
<p>Activation of T cells plays a role in chronic plaque psoriasis. Alefacept is thought to bind to CD2 receptors found on all
         peripheral T cells and to immunoglobulin receptors on cytotoxic cells, such as natural killer cells. Alefacept blocks further
         activation of T cells and reduces cellular-mediated apoptosis of T cells.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Alefacept modulates the immune response by decreasing activation of T cells that are believed to be the key mediators of psoriasis.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of moderate to severe chronic plaque psoriasis.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Treatment of psoriatic arthritis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to alefacept; CD4+ T lymphocyte count below normal; history of systemic malignancies; patients with a clinically
         important infection; serious infections; live or attenuated vaccines; lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients at high risk for malignancies; pregnancy (category B); elderly.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Chronic Plaque Psoriasis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 15 mg once/wk <small>x</small> 12 wk, may repeat course after 12 wk off therapy <span class="rdroute">IV</span> 7.5 mg once/wk <small>x</small> 12 wk, may repeat course after 12 wk off therapy<br/><br/><span class="indicationtitle">Psoriatic Arthritis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 7.5 mg once/wk <small>x</small> 12 wk<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>Administer only if CD4+ T lymphocyte count is <img src="../images/special/greaterorequal.gif"/>250 cells/microliter.</li>
<li>Reconstituted alefacept should be clear and colorless to slightly yellow.</li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Reconstitute the 15 mg vial IM administration with 0.6 mL of the supplied diluent to yield 15 mg/0.5 mL. Gently swirl vial
            for about 2 min to mix, but do not shake.
         </li>
<li>Rotate the injection sites and space at least 1 inch from an old site.</li>
<li>Never inject into areas where the skin is tender, bruised, red, or hard.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Reconstitute the 7.5 mg vial for IV administration with 0.6 mL of the supplied diluent to yield 7.5 mg/0.5 mL. Gently swirl
                  vial for about 2 min to mix, but do not shake.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Direct:</span>  Prime supplied infusion set with 3.0 mL of supplied diluent and insert into vein. Give reconstituted solution over <img src="../images/special/lesserorequal.gif"/>5
                  sec and do not use a filter. Follow with flush using 3 mL of supplied diluent.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> No data available at this time. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Store vials of powder away from light at 15°30° C (59°86° F).</li>
<li>Store reconstituted solution for up to 4 h between 2°8° C (36°46° F); discard solution not
            used within 4 h of reconstitution.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Secondary malignancies, serious infections, chills, <span class="speceff-common">injection site pain,</span> injection site inflammation. <span class="typehead">CNS:</span> Dizziness, headache. <span class="typehead">GI:</span> Nausea, vomiting. <span class="typehead">Hematologic:</span>
<span class="speceff-common">Lymphopenia,</span> alefacept antibody formation. <span class="typehead">Musculoskeletal:</span> Myalgia. <span class="typehead">Respiratory:</span> Pharyngitis, increased cough. <span class="typehead">Skin:</span> Pruritus. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>  Additive immunosuppression with other immunosuppressant drugs (e.g., <span class="classification">corticosteroids</span>); <span class="classification">live vaccines</span> increase risk of secondary transmission of infection. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 63% absorbed from IM injection. <span class="typehead">Metabolism:</span> Presumed to be broken down in plasma. <span class="typehead">Half-Life:</span> 270 h after IV. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Discontinue drug immediately and institute supportive measures if a serious hypersensitivity reaction occurs.</li>
<li>
            							Note: Drug should be discontinued if CD4+ T lymphocyte counts remain below 250 cells/microliter for one month.
            						
         </li>
<li>Lab tests: Weekly WBC with differential during 12-wk dosing period; periodic liver enzymes.</li>
<li>Monitor for and promptly report S&amp;S of infection.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any of the following promptly: chest pain or tightness, rapid or irregular heart beat; difficulty breathing or swallowing;
            swelling of face, tongue, hands, feet or ankles; rapid weight gain; signs of infection (e.g., fever, chills, cough, sore throat,
            pain or difficulty passing urine); skin rash or itchy skin; severe stomach pain.
         </li>
<li>Do not accept live or live-attenuated vaccines while taking this drug.</li>
<li>Notify physician if you become pregnant while taking this drug or within 8 wk of discontinuing drug.</li>
<li>Do not breast feed without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>